{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035426","form_type":"8-K","ticker":"BLGO","cik":"0000880242","company_name":"BIOLARGO, INC.","filed_at":"2024-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.238460+00:00","generated_at":"2026-05-30T00:08:11.847065+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows","bullets":["Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.","Net loss narrowed to $1.1M in Q3 (from $1.5M) and $2.6M YTD (from $3.6M).","Current assets $7.4M, cash $3.9M; stockholders' equity $6.0M as of Sept 30, 2024.","CEO says tenth consecutive year of record revenue; expects 2025 to be another record.","Investing in production for national rollout of Clyra Medical Technologies products."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035426","json":"https://secwatch.observer/filing/0001437749-24-035426.json","markdown":"https://secwatch.observer/filing/0001437749-24-035426.md","text":"https://secwatch.observer/filing/0001437749-24-035426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/880242/000143774924035426/0001437749-24-035426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/880242/000143774924035426/blgo20241114_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:08:11.847065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}